Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003820 · ClinicalTrials.gov registry record · Phase 2
Rituximab in Treating Patients With Hodgkin's Lymphoma
A Phase 2 study of Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma, sponsored by Ranjana Advani.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT00003820 is a Phase 2 study of Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma that has completed, run by Ranjana Advani. The registered enrollment target is 39 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00003820, a Phase 2 study of Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma, has completed, sponsored by Ranjana Advani.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (2)
California
- Stanford University Medical Center - Stanford
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1999-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003820
The ClinicalTrials.gov registry entry for NCT00003820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Ranjana Advani, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00003820 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00003820 about?
NCT00003820 is a clinical study titled "Rituximab in Treating Patients With Hodgkin's Lymphoma". Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.
What is the current status of trial NCT00003820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 1999-01. Estimated completion is 2008-08.
What conditions does trial NCT00003820 study?
This clinical trial studies the following conditions: Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma, Hodgkin Lymphoma (Category).
What interventions are being tested in trial NCT00003820?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00003820?
This trial is sponsored by Ranjana Advani, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003820 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.